Biotech/Medical Technology Stock News; Aethlon Medical (OTCBB: AEMD) Announces Sarcoma, Lung Cancer, Prostate Cancer, Metastatic Melanoma, and Head and Neck Cancer Studies

SAN DIEGO – August 24, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

Abingdon, United Kingdom, 11th July 2011 – Toumaz Limited (AIM: TMZ,), a pioneer in low cost, ultra-low power wireless communications and broadcast technology, has established a new joint venture with Dr. Patrick Soon-Shiong’s company California Capital Equity LLC (‘CCE’), to expand the commercialisation and distribution of the SensiumTM Digital Plaster. The joint venture, which is named “Toumaz US LLC”, will be headquartered in San Diego, California, and will sell and distribute the Sensium™ Digital Plaster in North America and Worldwide.

 Toumaz Limited is also pleased to announce that the SensiumTM Digital Paster has received 510(k) approval from the Food and Drug Administration ('FDA') in the US.

Verisante Enters Into Asset Purchase Agreement With Perceptronix Medical

Verisante Technology, Inc. (TSX VENTURE:VRS  OTCQX:VRSEF) (the "Company" or "Verisante") announced today that the Company has entered into an Asset Purchase Agreement with Perceptronix Medical Inc. ("PMI").

Under the terms of the Agreement, Verisante has purchased all rights to the ClearVu(TM) and ClearVu Elite(TM) endoscopy systems for early lung cancer detection developed by PMI which are designed to provide real-time spectral, white light, and autofluorescence imaging for undisclosed consideration pursuant confidentiality terms of the Agreement.

PURE Bioscience Reports Study Showing Effectiveness of SDC Against Biofilm

Preliminary Data from UMDNJ Demonstrates Remarkable Biofilm Destruction and Prevention

PURE Bioscience, Inc. (NASDAQ:PURE ), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced preliminary in vitro laboratory results demonstrating SDC’s effectiveness against biofilm in tests conducted by the University of Medicine & Dentistry of New Jersey.

Dr. Narayanan Ramasubbu, Associate Professor, Department of Oral Biology, stated, “We have used SDC against single species biofilms of Aggregatibacter actinomycetemcomitans, a causative agent in localized aggressive periodontitis, and S. epidermidis, a pathogen associated with hospital settings.